This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

NSCLC nintedanib clinical trials

Nintedanib* has been investigated in lung cancer as part of the LUME-Lung clinical trial programme. Within this section you will find an overview of the main trials within this programme as well as links to pages for further information.

Nintedanib clinical trials in thoracic malignancies

The approval of nintedanib for the treatment of adult patients with advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy is based on the Phase III LUME-Lung 1 trial.1

The following table shows the clinical trials of nintedanib in NSCLC; you can find links to further information on this site and published papers.

Ongoing clinical trials

Nintedanib thoracic malignancies ongoing trials

DLT, dose-limiting toxicity; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; PK/PD, pharmacokinetics/pharmacodynamics.



Reck M, et al. Lancet Oncol 2014;15(2):143-55.

*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.